Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Mogamulizumab in Relapsed/Refractory T-Cell Lymphoma
NCT04541017Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2021
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of magrolimab in mycosis fungoides (MF), Sézary syndrome (SS), sponsored by National Cancer Institute. Started Apr 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT04541017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541017.